Tc-99m-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression

Basit Öğe Kaydı
dc.contributor.authorBurak, Z
dc.contributor.authorMoretti, JL
dc.contributor.authorErsoy, O
dc.contributor.authorSanli, U
dc.contributor.authorKantar, M
dc.contributor.authorTamgac, F
dc.contributor.authorBasdemir, G
dc.date.accessioned2019-10-27T18:38:43Z
dc.date.available2019-10-27T18:38:43Z
dc.date.issued2003
dc.departmentEge Üniversitesien_US
dc.description.abstractIn vitro studies have demonstrated that Tc-99m-methoxyisobutylisonitrile (Tc-99m-MIBI) is a transport substrate of multidrug resistance (MDR)-related proteins. The aim of this clinical study was to evaluate whether Tc-99m-MIBI scintigraphy was a functional imaging tool for in vivo detection of multidrug resistance-associated protein (MRP) expression in osteosarcoma and to investigate the role of MRP and Tc-99m-MIBI imaging to predict the clinical outcome. We also examined whether the scintigraphic parameters would help to distinguish the functional capacity of P-glycoprotein (Pgp) and MRP. Methods: Twenty-four patients with a diagnosis of osteosarcoma were studied before neoadjuvant chemotherapy. Tumor-to-background ratios of both early (10 min) and delayed (1 h) images and the percentage washout rate (WR%) of Tc-99m-MIBI were calculated. Immunohistochemical analysis of MRP and Pgp was performed on biopsy specimens, and the response to preoperative chemotherapy was assessed by histopathologic examination. Results: Fifteen of 24 osteosarcoma samples in our series (62.5%) showed significant expression of MRP. The level of MRP expression was significantly correlated with the WR% of Tc-99m-MIBI (r = 0.58, P = 0.003), and the WR% of Tc-99m-MIBI was significantly faster in patients with high MRP expression than in those with a low MRP score (P = 0.007). The clearance rate of Tc-99m-MIBI was significantly slower in tumor samples with negative or low expression of both Pgp and MRP (16% +/- 6.2%) when compared with osteosarcomas with high expression of both proteins (31.7% +/- 8.7%) (P = 0.001). There was not a significant difference between the WR% of 99mTc-MIBI in tumors with coexpression of both proteins and in tumors with high expression of either Pgp or MRP. Both the rate of MRP expression and the WR% of Tc-99m-MIBI were significantly correlated with response rate. Conclusion: Our results suggest that the WR% of Tc-99m-MIBI is correlated with MRP expression. Both the WR% of Tc-99m-MIBI and MRP expression are correlated with therapy response. Tc-99m-MIBI can be used as a general probe for functional imaging of both Pgp and MRP; however, it is not capable of differentiating the functional status of either MDR-related glycoprotein.en_US
dc.identifier.endpage1401en_US
dc.identifier.issn0161-5505
dc.identifier.issn1535-5667
dc.identifier.issue9en_US
dc.identifier.pmid12960182en_US
dc.identifier.startpage1394en_US
dc.identifier.urihttps://hdl.handle.net/11454/36649
dc.identifier.volume44en_US
dc.identifier.wosWOS:000186100700018en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSoc Nuclear Medicine Incen_US
dc.relation.ispartofJournal of Nuclear Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectmultidrug resistanceen_US
dc.subjectmultidrug resistance-associated proteinen_US
dc.subjectP-glycoproteinen_US
dc.subjectosteosarcomaen_US
dc.subjectTc-99m-methoxy-isobutylisonitrileen_US
dc.titleTc-99m-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expressionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu